Mesenchymal stromal cells (MSCs) can be obtained from several sources and the significant differences in their properties make it crucial to investigate the differentiation potential of MSCs from different sources to determine the optimal source of MSCs. We investigated if this biological heterogeneity in MSCs from different sources results in different mechanisms for their differentiation.
Introduction
Mesenchymal stromal cells (MSCs) are multipotent cells that were originally identified in bone marrow stroma [1] [2] [3] [4] . These were first described as mesenchymal stromal cells owing to their ability to differentiate into mesenchymal cells such as bone and cartilage. The minimum criteria for defining Mesenchymal stromal cells as defined by the International Society for Cellular Therapy (ISCT) include: plastic-adherence under standard culture conditions, presence of CD105, CD73, CD90 and absence of hematopoietic cell surface markers CD34, CD45, CD11a, CD19, and HLA-DR and most importantly the ability to differentiate into osteocytes, adipocytes, and chondrocytes in vitro [5] .
Mesenchymal stromal cells are known to differentiate into a variety of cell types including osteoblasts (bone cells), chondrocytes (cartilage cells), adipocytes (fat cells), myocytes (skeletal and cardiac muscle cells), and neurons (neu-
ral cells) [6] [7] .
MSCs are obtained from several adult mesenchymal tissue sources such as: bone marrow [8] , adipose tissue [9] , synovial membrane [10] , periosteum [11] and dental pulp [12] as well as from non-adult tissue sources such as the fetal tissue [13] , amniotic fluid [14] umbilical cord tissue (Wharton's jelly) [15] and umbilical cord blood [16] .
Although MSCs can be obtained from different sources, they differ in their proliferative capacity and multilineage differentiation potential [17] . The proliferative capacity depends on factors such as the tissue source, age of the donor and culture conditions [18] [19] . Moreover, MSCs from different sources differentiate into a particular lineage more, or less efficiently depending on their source of origin. The bone marrow derived MSCs have better osteogenic differentiation potential as compared to the adipose derived MSCs that have better adipogenic differentiation potential [20] . The numbers of MSCs that can be isolated from different sources also vary enormously [21] .
Several biological studies have also shown superior biological properties of MSCs derived from neo-natal tissues over those derived from the adult tissues [22] . Another issue is that the MSCs isolated from various sources appear to be morphologically similar and display similar surface markers, yet they tend to have significant differences that cannot be attributed to the experimental variations.
Owing to these significant differences in the properties of the MSCs from dif- of MSC from the right source for achieving a specific clinical outcome. Some studies involve the comparison and analysis of properties such as the yield and differentiation potential, surface antigen expression, proliferation capacity, tolerance for aging and paracrine activity [20] [23] [24] . Such studies reveal the superiority and biological advantage of one source over the other and varied differentiation potential to different lineages.
There are a few studies involving comparisons of the transcriptome profiles of MSCs from different sources to identify the similarities and differences at the genetic level during differentiation into three major mesenchymal lineages [25] [26] [27] . Such studies provide a rational basis for assessing the qualities of MSCs from various sources.
However, till date there has been no comparative study of transcriptomes of ontogenically different sources and the mechanisms and pathways they follow for differentiation into similar lineages.
In our study, we compared the gene expression profiles of MSCs from three ontogenically different sources: Human Embryonic Stem cells (hES), Fetal limb (Flb) and Bone marrow (BM) at two time points of differentiation: Day 7 and Day 14/21. Currently there are no known markers that can identify MSCs at discrete stages of differentiation, therefore the only way to compare MSCs is at similar stage of differentiation. Even using cells from the same passage number does not guarantee that they will be at the same stage of differentiation. Therefore in this study we have used extent of differentiation as a method to compare these different MSC populations. In all 3 MSC populations, Day 7 was when differentiation was first detectable using histochemical stains. For Flb and BM MSCs differentiation was complete by day 14, whereas hES MSCs continued differentiation especially in the osteogenic lineage until Day 21. This was the basis of choosing the time points for comparison. The purpose of our study was to identify the similarities and differences at the genetic level as well as to explore the signaling pathways used by the MSCs from ontogenically different sources to differentiate into the similar mesodermal lineages. Since biological pathways rather than individual genes determine the phenotypic changes observed in cells, a deep understanding of the canonical pathways is essential. It is imperative to understand what pathways are used by the different sources to obtain similar differentiation products. Since MSCs have several clinical applications for treatment of various conditions such as: bone and cartilage diseases, cardiovascular diseases, liver diseases, autoimmune diseases and cancer [28] ; studies of this kind will enhance its therapeutic efficacy. Such studies will enable the application of MSCs as building blocks for molecular medicine [29] , in gene therapy [30] , and in regenerative medicine [31] . 
Materials and Methods

Cell Culture
Human embryonic stem cell derived MSCs (hES-MSCs) were a gift from Choo A and Lim SK. Derivation of these cell lines have been described in a previous publication [32] . Cells were received at passage 11 and expanded for 2 passages in MSCGM BulletKit (Lonza, MD, USA).
Human fetal limb derived MSCs (Flb-MSCs) was a gift from Lim SK, who derived and characterized the cells [33] . The fetal limb derived MSC cell line was the F3lb cell line. Cells were received at passage 10 and expanded for 2 passages in MSCGM BulletKit (Lonza, MD, USA), with medium change every 3 -4 days, and passage during 90% confluency (4 -5 days) using TryPLE (Invitrogen, CA, USA) before differentiation.
Human bone marrow derived MSCs (BM-MSCs) were purchased frozen from Lonza (Gaithersburg, MD) at passage 2 [34] . These cells were thawed, cultured for an additional passage (passage 3), and pooled before being used in the experiments. All the MSCs confirmed to the ISCT definition of MSCs [5] . 
MSC Differentiation
After expansion, both hES-MSCs, Flb-MSCs were seeded in T75 culture flasks for RNA extraction and in 12-well plates for staining during differentiation of adipocytes, and osteocytes, and in pellet form in 15 
RNA Extraction
Total RNA of the undifferentiated MSC, adipocytes, and osteocytes of hES-MSCs and Flb-MSCs was harvested using 1 ml of Trizol (Invitrogen, CA, USA)/10 cm RNA extraction from Trizol samples was carried out using the RNA easy kit (Qiagen, Valencia, CA).
Gene Expression Microarray
For the hES-MSCs and Flb-MSCs, RNA amplification was done using Illumina 
Details of the Microarray Datasets Used for the Analysis
The microarray datasets comprised of the three ontogenically different sources The microarray data of BM-MSCs is deposited in ArrayExpress and is accessible through the accession number E-TABM-318
https://www.ebi.ac.uk/arrayexpress/experiments/E-TABM-318/.
Normalisation, Quality Control and Obtaining Differentially Expressed Genes
The microarray data was imported in Partek, and normalized using "quantile" normalization. The batch effect due to different chips (sentrix barcode), also known as random effect, was removed and quality control check was carried out to make sure the replicates clustered according to the lineages they were derived from. The hierarchical clustering plots were generated for each of the three sources to make sure the clustering was optimal for further processing 
Obtaining HUGO Gene Nomenclature Committee (HGNC) Approved Symbols
Owing to the difference in the versions of the Illumina platforms, the symbols of the differentially expressed genes obtained were run through the "Multi-symbol checker" tool to check if they were HGNC approved symbols. In case if a symbol was not the current approved symbol but a previously used symbol, it was replaced by the currently approved symbol.
Canonical Pathways Analysis
The HGNC approved differentially expressed gene lists obtained were uploaded into Ingenuity pathway analysis software (IPA). A core analysis for each of the lists in context of canonical pathways was carried out in IPA. IPA reports the enriched pathways for the dataset and assigns a ratio and a significance score derived from the p-value, using the right-tailed Fisher exact test. The ratio is calculated by taking the number of genes from the user's dataset that participate in a canonical pathway and dividing it by the total number of genes in that canonical pathway. The p-value measures how likely the observed association between a specific pathway and the dataset would be if it was only due to random chance. The smaller is the p-value, the more is the confidence of the corresponding pathway being associated with the user's dataset. Pathways having higher ratios and lower p-values are more likely to explain the phenotype of the dataset than others. Significance score is the negative log of the p-value. A threshold score of p-value 0.01 corresponding to a significance score of 2 was used.
The significantly enriched pathways were compared for each lineage (differentiated cell type) at the two stages (Day 7 and Day 14/21) among the three sources to identify the ones commonly significant (negative log p-value = 2) among all the three sources or any of the two sources and also specific to each source.
Results
Microarray Datasets and Obtaining Differentially Expressed Genes
The Microarray datasets comprised of the three ontogenically different sources The microarray data was imported in Partek, and normalized using "quantile" normalization. The hierarchical clustering plots were generated for each of the three sources to make sure the clustering was optimal for further processing 
MSCs from the Three Ontogenically Different Sources, Differ in Their Growth Kinetics and Differentiation Abilities
The hES-MSCs take the maximum time to differentiate (around 21 days), as 
Minimal Overlap Found on Comparing the Differentially Expressed Genes among the Three Ontogenically Different Sources
We found that the differentially expressed genes were highly dissimilar between the cells differentiated from hES-MSCs, Flb-MSCs and BM-MSCs.
In adipocytes at Day 7, there were 708 differentially expressed genes from hES-MSCs, 1155 genes from Flb-MSCs and 769 genes from BM-MSCs. Of these (Figure 3a (ii)).
In chondrocytes at Day 7, there were 709 differentially expressed genes from hES-MSCs, 1305 genes from Flb-MSCs and 887 genes from BM-MSCs. Of these, only 113 genes were similar among all three sources of MSCs (Figure 3b(i) ).
In chondrocytes at Day 14/21, there were 1179 differentially expressed genes from hES-MSCs, 1147 genes from Flb-MSCs and 1613 genes from BM-MSCs. Of these, only 86 genes were similar among all three sources of MSCs ( Figure   3b (ii)). In osteocytes at Day 14/21, there were 904 differentially expressed genes from hES-MSC, 885 genes from Flb-MSC and 602 genes from BM-MSCs. Of these, only 93 genes were similar among all three sources of MSCs (Figure 3c (ii)).
Known Lineage Specific Markers
We looked at expression of known lineage specific markers in the differentially expressed gene lists to check to what extent they were regulated across the three sources. Tables 2-4 comprise of the fold change values of the lineage specific markers across the three sources. Table 2 . Fold change in expression of the known lineage specific markers across the three sources for adipogenesis. (Table 2 ). This indicates that the hES-MSC source differentiates poorly into adipocytes as compared to the Flb-MSC and the BM-MSC sources.
Chondrogenesis Markers
Out of the 28 known chondrogenesis markers, The hES-MSC source had 4 and Table 3 . Fold change in expression of the known lineage specific markers across the three sources for chondrogenesis. 
The Differentially Expressed Genes Are Manifested into Different Canonical Pathways
The HGNC approved differentially expressed gene lists obtained were uploaded into Ingenuity pathway analysis software (IPA). A core analysis for each of the lists in context of canonical pathways was carried out in IPA. IPA reports the enriched canonical pathways for the dataset and assigns a ratio and a significance score derived from the p-value, using the right-tailed Fisher exact test (For details see the "Materials and Methods" section).
The gene expression data showed that trilineage differentiation from hES-MSC, Flb-MSC and BM-MSC yield certain differences and similarity to the differentially regulated genes, causing changes in the signaling pathways regulated. Since all the three MSC sources ultimately differentiate into the three lineages, we expected some canonical pathways to be similar amongst them and some to be very specific. For this purpose the comparison among the enriched canonical pathways was carried out for each lineage (differentiated cell type) at the two different stages (Day 7 and Day 14/21) among the three sources to identify the ones commonly significant (negative log p-value = 2) among all the three sources or any of the two sources and also specific to each source.
Adipogenesis Day 7
The canonical pathways significant in common between MSCs derived from all three sources were 13. Among these 13, the most significant ones were "Hepatic The canonical pathways significant in common between MSCs derived from Flb and BM only were 12. Among these 12, the most significant ones were "LPS/ IL-1 Mediated Inhibition of RXR Function" and "Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis".
The canonical pathways significant in hES only were 29; among these the most significant pathways were "Interferon Signaling", "IL-10 Signaling" and "Toll-like Receptor Signaling".
The canonical pathways significant in Flb only were 6; among these the most significant pathway was the "Epithelial Adherens Junction Signaling". 
Adipogenesis Day 14/21
The canonical pathways significant in common between MSCs derived from all three sources were 11 (Figure 4(a) The canonical pathways significant in common between MSCs derived from Flb and BM only were 28 ( Figure 4(b) ).
The canonical pathways significant in hES derived MSCs only were 19; among these the most significant pathways were "Cell Cycle Control of Chromosomal Replication", "Estrogen-mediated S-phase Entry", "Cell Cycle: G1/S Checkpoint Regulation" and "IL-10 Signaling".
The canonical pathways significant in Flb derived MSCs only were 30; among these the most significant pathway were "IL-17 Signaling", "NRF2-mediated
Oxidative Stress Response" and "Role of IL-17A in Arthritis".
The canonical pathways significant in BM derived MSCs only were 28; among these the most significant pathway were "Glioblastoma Multiforme Signaling", "Dopamine Receptor Signaling", and "Wnt/β-catenin Signaling" (Supplementary File 4 Sheet 2).
Chondrogenesis Day 7
The canonical pathways significant in common between MSCs derived from all three sources were 20. Among these 20, the most significant ones were "Hepatic The canonical pathways significant in common between MSCs derived from Flb and BM only were 9. Among these 9, the most significant ones were "Thyroid Cancer Signaling", "Signaling by Rho Family GTPases", "HMGB1 Signaling" and "IL-10 Signaling".
The canonical pathways significant in hES only were 15; among these the most significant pathways were "Estrogen-mediated S-phase Entry" and "TNFR2
Signaling".
The canonical pathways significant in Flb only were 23; among these the most significant pathway were "Graft-versus-Host Disease Signaling" and "Communication between Innate and Adaptive Immune Cells".
The canonical pathways significant in BM only were 28; among these the most The canonical pathways significant in common between MSCs derived from Flb and BM only were 23 ( Figure 5(b) ).
There were 8 canonical pathways significant for hES derived MSCs only, among these the most significant ones were "Interferon Signaling" and "ATM Signaling". 
Osteogenesis Day 7
The canonical pathways significant in common between MSCs derived from all three sources were 15. Among these 15, the most significant ones were "Hepatic The canonical pathways significant for hES only were 15; among these the most significant pathways was "Wnt/β-catenin Signaling" and "Epithelial Adherens Junction Signaling".
The canonical pathways significant for Flb only were 20; among these the most significant pathways were "Cell Cycle: G2/M DNA Damage Checkpoint
Regulation", "GADD45 Signaling" and "Mitotic Roles of Polo-Like Kinase".
The canonical pathways significant for BM only were 11; among these the most significant pathway was "ERK/MAPK Signaling" (Supplementary File 4 Sheet 5).
Osteogenesis Day 14/21
The canonical pathways significant in common between MSCs derived from all three sources were 12 ( Figure 6 The canonical pathways significant for hES only were 14; among these the most significant pathways was "Differential Regulation of Cytokine Production in Intestinal Epithelial Cells by IL-17A and IL-17F" and "iNOS Signaling".
The canonical pathways significant for Flb only were 26; among these the most significant pathways were "Role of Tissue Factor in Cancer" and "Eicosanoid Signaling".
The canonical pathways significant for BM only were 11; among these the most significant ones were "LXR/RXR Activation" and "NRF2-mediated Oxida- [24] . A few studies have provided a rational basis of accessing the qualities of MSCs from various sources by comparing the transcriptome profile of MSCs from different sources and identifying their similarities and differences at the genetic level [25] [26] [27] . However, none of the studies so far has reported a comparison of MSC sources from different ontogeny using a systematic study to compare their transcriptomes.
Discussion
In this study, we compared the gene expression profiles of MSCs from three ontogenically different sources: human embryonic stem cells, fetal limb and bone marrow. MSCs are also known for their ability to secrete paracrine factors that promote the recruitment of host cells. These paracrine factors are very important in tissue regeneration and repair of MSCs. Transcriptome profiling provides an effective way to measure global expression of these paracrine factors. Therefore in this study we have compared the transcriptomes of MSCs from different sources. The aim of our study was not only to look for the similarities and differences between the transcriptome of these MSCs, but also to explore all the pathways used by the MSCs to differentiate into the three lineages.
The choice of MSC sources depended on their availability, growth kinetics and differentiation potential. hES-MSCs have an unlimited supply, short doubling time (3 -4 days) and can be passaged for longer periods (18 -19 passages) . BM-MSCs are a gold standard and are widely used owing to their excellent differentiation abilities. Flb-MSCs are an intermediate between the hES-MSCs and BM-MSCs; they have a short doubling time (2 -3 days), can be passaged for longer periods (18 -19 passages) . Flb-MSCs are similar to BM-MSCs in terms of their growth and differentiation abilities, but senesce much later and can be passaged for 18 -19 passages. Thus these would be ideal model system for studying MSCs and comparing their characteristics to BM-MSCs.
We first compared the gene expression profiles of MSCs from all 3 sources. Identification of differentially expressed genes with respect to the undifferentiated control was carried out at Day 7 and Day 14/21. The lists of the differentially expressed gene were compared across the three sources for the three lineages. We found that the differentially expressed genes were highly dissimilar with very less overlap (5% -16%) among the three sources. and had a higher capability of immunomodulation, but were less inducible for differentiation as compared to the BM-MSCs [35] .
Since biological pathways and networks rather than individual genes determine the phenotypic changes observed in cells, we studied the canonical pathways these differentially expressed genes were involved in.
For this purpose, the differentially expressed gene lists were uploaded into Ingenuity pathway analysis tool. IPA reports the enriched pathways for the dataset and assigns a ratio and a significance score derived from the p-value. Owing to the difference in the differentially expressed genes, the canonical pathways also exhibited a large variation.
The similar canonical pathways among the three sources were lineage specific. For adipocytes the most significant common pathways were: "Acute Phase Response Signaling", "Adipogenesis pathway", and HMGB1 Signaling. For chondrocytes the most significant common pathways were: the "Axonal Guidance Signaling", "Colorectal Cancer Metastasis Signaling", Inhibition of Matrix Metalloproteases" and "Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis". For osteocytes the common pathways were: "Agranulocyte Adhesion and Diapedesis", "Granulocyte Adhesion and Diapedesis", "Inhibition of Matrix Mettaloproteases" and Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis. The Flb-MSCs showed maximum overlap of canonical pathways with the BM-MSCs, indicating that the Flb-MSCs is an intermediate source between the less specialised hES-MSC source and the more specialised BM-MSC source.
This source specific utilization of canonical pathways for differentiation suggests that the MSCs from the three ontogenically different sources use different pathways and networks to obtain similar differentiation products. These observations explain the heterogeneity of MSCs observed at the cellular level arise from differences in the transcriptome of MSC from different sources. This heterogeneity is important in choosing MSC from the right source for a specific therapeutic application. This is especially relevant since certain MSC like dental pulp MSC can only be harvested at limited points and need to be banked. To improve the utilization of MSCs for cellular therapy it is also essential to have a standard/reference material to overcome the inconsistencies of clinical trials that arise due to several variable factors. The minimal criteria recommended by the ISCT are too basic and non-specific and there is a need of more than the minimal criteria to define MSCs [36] .
A deeper understanding and thorough study of the differentiation potential of MSC from different sources is warranted to enable the application of MSCs for molecular medicine [29] , to use MSCs in various forms of cellular therapies as well as genetic tools [30] and to enhance its potential use in cell and gene therapy for a number of human debilitating diseases and genetic disorders [31] . Stem Cell Discovery 
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